🔗 Share this article

The initial novel therapies for gonorrhoea in many years are being hailed as a "major milestone" in the battle against superbug strains of the pathogen, according to scientists.

A Worldwide Challenge

Cases of gonorrhoea are increasing globally, with data suggesting over 82 million new cases annually. Especially elevated rates are observed in the African continent and countries within the World Health Organization's designated area, which includes China and Mongolia to New Zealand. In England, cases have hit a record high, while infection numbers across Europe in 2023 were triple the level compared to figures for 2014.

“The clearance of new treatments for gonorrhoea is an significant and necessary advancement in the reality of growing infection rates, escalating drug resistance and the extremely scarce therapeutic options presently on offer.”

Health officials are particularly alarmed about the rise in antibiotic-resistant strains. The WHO has designated it as a "priority pathogen". Ongoing monitoring found that resistance to primary antibiotics like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

A Pair of Novel Drugs Secure Approval

Zoliflodacin, alternatively called a brand name, was cleared by the American regulatory agency in December for treating gonorrhoea. This infection can lead to significant complications, including the inability to conceive. Researchers hope that targeted use of this new drug will help delay the development of resistance.

Another new antibiotic, originating from the pharmaceutical company GSK, gained clearance in close succession. This drug, which is also used to treat UTIs, was demonstrated in studies to be successful in treating drug-resistant strains of the gonorrhoea bacteria.

A Unique Development Model

Zoliflodacin stemmed from a new, not-for-profit approach for drug creation. The non-profit organisation Global Antibiotic Research & Development Partnership worked alongside the pharmaceutical company its industry partner to see it through.

“This authorization represents a huge turning point in the therapy of superbug gonorrhoea, which until now has been evolving faster than our drug pipeline.”

Research Study Outcomes and Global Access

According to data released by a prominent scientific publication, zoliflodacin cured more than 90% of uncomplicated infections. This establishes an similar efficacy with the existing first-line therapy, which involves an injection and a pill. The trial included hundreds of volunteers from several countries including the United States, Thailand, South Africa, and European nations.

As part of the agreement of its unique model, GARDP has the authority to register and commercialise the drug in a wide range of low-income and middle-income countries.

Doctors on the front lines have voiced hope. Access to a one-pill regimen such as this is described as a "game-changer" for public health efforts. This is considered vital to alleviate the strain of the disease for patients and to stop the proliferation of extremely resistant gonorrhoea around the world.